Cause and consequence of heterogeneity in human mesenchymal stem cells: Challenges in clinical application

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60076658%3A12520%2F24%3A43909073" target="_blank" >RIV/60076658:12520/24:43909073 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1016/j.prp.2024.155354" target="_blank" >https://doi.org/10.1016/j.prp.2024.155354</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.prp.2024.155354" target="_blank" >10.1016/j.prp.2024.155354</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cause and consequence of heterogeneity in human mesenchymal stem cells: Challenges in clinical application

Popis výsledku v původním jazyce

Human mesenchymal stem cells (hMSCs) are mesoderm-derived adult stem cells with self-proliferation capacity, pluripotent differentiation potency, and excellent histocompatibility. These advantages make hMSCs a promising tool in clinical application. However, the majority of clinical trials using hMSC therapy for diverse human diseases do not achieve expectations, despite the prospective pre-clinical outcomes in animal models. This is partly attributable to the intrinsic heterogeneity of hMSCs. In this review, the cause of heterogeneity in hMSCs is systematically discussed at multiple levels, including isolation methods, cultural conditions, donor-to-donor variation, tissue sources, intra-tissue subpopulations, etc. Additionally, the effect of hMSCs heterogeneity on the contrary role in tumor progression and immunomodulation is also discussed. The attempts to understand the cellular heterogeneity of hMSCs and its consequences are important in supporting and improving therapeutic strategies for hMSCs.

Název v anglickém jazyce

Cause and consequence of heterogeneity in human mesenchymal stem cells: Challenges in clinical application

Popis výsledku anglicky

Human mesenchymal stem cells (hMSCs) are mesoderm-derived adult stem cells with self-proliferation capacity, pluripotent differentiation potency, and excellent histocompatibility. These advantages make hMSCs a promising tool in clinical application. However, the majority of clinical trials using hMSC therapy for diverse human diseases do not achieve expectations, despite the prospective pre-clinical outcomes in animal models. This is partly attributable to the intrinsic heterogeneity of hMSCs. In this review, the cause of heterogeneity in hMSCs is systematically discussed at multiple levels, including isolation methods, cultural conditions, donor-to-donor variation, tissue sources, intra-tissue subpopulations, etc. Additionally, the effect of hMSCs heterogeneity on the contrary role in tumor progression and immunomodulation is also discussed. The attempts to understand the cellular heterogeneity of hMSCs and its consequences are important in supporting and improving therapeutic strategies for hMSCs.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30401 - Health-related biotechnology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pathology Research and Practice

ISSN

0344-0338

e-ISSN

1618-0631

Svazek periodika

260

Číslo periodika v rámci svazku

neuvedeno

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

14

Strana od-do

—

Kód UT WoS článku

001253387600001

EID výsledku v databázi Scopus

2-s2.0-85195549935